Niarc Pharma Engineering Private Limited - Due diligence report

A 360° intelligence report on Niarc Pharma Engineering Private Limited: trust score, financial health, credit view, compliance, directors, g…

2018-03-13 Vasai, Maharashtra Active Unlisted
View plans
NP Niarc Pharma Engineering Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Niarc Pharma Engineering Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
88/100
Trust Score
Low Risk

Niarc Pharma Engineering Private Limited is assessed as Low Risk with a Trust Score of 88/100. Niarc Pharma Engineering Private Limited is an active private limited indian non-government company incorporated in 2018, operating in the Machinery and Equipment sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 25 Jun 2026 from the latest processed filings. Niarc Pharma Engineering Private Limited snapshot & full profile →

Overall Assessment CautionWeakNeutralGoodStrong Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
88/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • No open charges - unencumbered balance sheet.
  • Elevated gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RAMESH LAXMAN JATHAR 01234567 Director 01/04/2018 6 yrs Approved
AJAY KUMAR SINGH 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2021 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 3 year(s).
Latest year revenue grew 24%.
Asset base grew 0.86 - capacity expansion.
Operating for 8 years.
Active GST registration(s).
Distress signals & risk flags
No critical warning flags detected in the available data.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence93/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment68/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view78/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 5 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
13 Mar 2018
Incorporated
Registered with Roc Mumbai Ii
Director appointed
RAMESH LAXMAN JATHAR (Director)
Director appointed
AJAY KUMAR SINGH (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 61% over the last 3 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2021 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Image Nirman Pvt Ltd U70101WB2006PTC107996 Kolkata, West Bengal, India
Prograde Retail Private Limited U52609KA2019PTC122657 Bengaluru, Karnataka, India
Syg Food Products Private Limited U51909DL2017PTC319331 New Delhi, Delhi, India
Gemco Exports Private Limited U15134RJ1995PTC009575 Jaipur, Rajasthan, India
Intersource Garments Private Limited U17120GJ2011PTC068385 Bharuch, Gujarat, India
Mcs Green Home Private Limited U70109DL2013PTC253514 New Delhi, Delhi, India
Leblanc Products Private Limited U24290TN2020PTC139226 Chennai, Tamil Nadu, India
Computers Crust Private Limited U72900UP2019PTC123786 Ghaziabad, Uttar Pradesh, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Niarc Pharma Engineering Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Niarc Pharma Engineering Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Niarc Pharma Engineering Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 88/100, distress signals and MSME payment-delay disclosures - know whether Niarc Pharma Engineering Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Niarc Pharma Engineering Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Niarc Pharma Engineering Private Limited an active company?

Niarc Pharma Engineering Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Niarc Pharma Engineering Private Limited financially healthy?

Niarc Pharma Engineering Private Limited has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.

Should I do business with Niarc Pharma Engineering Private Limited?

Its overall Trust Score is 88/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Niarc Pharma Engineering Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Niarc Pharma Engineering Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Niarc Pharma Engineering Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Niarc Pharma Engineering Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.